The effect of N-acetylcysteine on ifosfamide-induced nephrotoxicity:: in vitro studies in renal tubular cells

被引:31
作者
Chen, Nancy
Aleksa, Katarina
Woodland, Cindy
Rieder, Michael
Koren, Gideon
机构
[1] Univ Western Ontario, Dept Physiol & Pharmacol, Ivey Chair Mol Toxicol, Schulich Sch Med & Dent, London, ON N6A 5C1, Canada
[2] Univ Western Ontario, Dept Paediat, London, ON N6A 5C1, Canada
[3] Childrens Hosp W Ontario, CIHR GSK Chair Paediat Clin Pharmacol, London, ON, Canada
[4] Hosp Sick Children, Div Clin Pharmacol & Toxicol, Toronto, ON M5G 1X8, Canada
[5] Univ Toronto, Fac Med, Dept Pharmacol, Toronto, ON, Canada
关键词
D O I
10.1016/j.trsl.2007.02.001
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Ifosfamide (IF) nephrotoxicity is a serious adverse effect in children undergoing chemotherapy. Previous studies have shown that, in addition to the renal production of chloroacetaldehyde, a toxic metabolite of IF, lower levels of glutathione (GSH) may predispose the kidney to damage. The antioxidant N-acetylcysteine (NAC) is used extensively as an antidote for acetaminophen poisoning in children by replenishing GSH levels. As it has been safely and effectively used clinically, the objective of this study was to test whether the reversal of ifosfamide-induced nephrotoxicity can be achieved by administering NAC. Supplementation with NAC may reduce or prevent the degree of cellular cytotoxicity induced by IF. Porcine renal proximal tubular (LL-CPK-1) cells were treated with NAC (0.4 mM or 2.5 mM) concurrently with 1 mM IF and 50 mu M L-buthionine sulfoximine (BSO). Cellular viability was assessed by alamarBlue assay at 96 h. Intracellular GSH and oxidized GSH (GSSG) levels were determined using a GSH/GSSG calorimetric detection kit. A significant 60% decrease in cellular viability occurred when cells were treated daily with BSO and IF for 96 h. This decrease was significantly reduced when cells were concurrently treated with NAC in a concentration-dependent manner. Intracellular and total GSH levels in cells receiving concurrent treatment of NAC were significantly higher than those without NAC treatment. NAC protects renal tubular cells from IF-induced cytotoxicity. It is likely that NAC is protecting the cells by partially acting as a precursor for GSH synthesis. This mode of therapy may allow for protecting children from life-threatening nephrotoxicity induced by IF.
引用
收藏
页码:51 / 57
页数:7
相关论文
共 41 条
[1]   A tubule cell model for ifosfamide nephrotoxicity [J].
Aleksa, K ;
Halachmi, N ;
Ito, S ;
Koren, G .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2005, 83 (06) :499-508
[2]   Renal-tubule metabolism of ifosfamide to the nephrotoxic chloroacetaldehyde: Pharmacokinetic modeling for estimation of intracellular levels [J].
Aleksa, K ;
Ito, S ;
Koren, G .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2004, 143 (03) :159-162
[3]   INHIBITION AND ENHANCEMENT OF MICROSOMAL DRUG-METABOLISM BY DIETHYL MALEATE [J].
ANDERS, MW .
BIOCHEMICAL PHARMACOLOGY, 1978, 27 (07) :1098-1101
[4]   THE ANTIOXIDANT ACTION OF N-ACETYLCYSTEINE - ITS REACTION WITH HYDROGEN-PEROXIDE, HYDROXYL RADICAL, SUPEROXIDE, AND HYPOCHLOROUS ACID [J].
ARUOMA, OI ;
HALLIWELL, B ;
HOEY, BM ;
BUTLER, J .
FREE RADICAL BIOLOGY AND MEDICINE, 1989, 6 (06) :593-597
[5]   Acetaminophen-induced oxidant stress and cell injury in cultured mouse hepatocytes:: Protection by N-acetyl cysteine [J].
Bajt, ML ;
Knight, TR ;
Lemasters, JJ ;
Jaeschke, H .
TOXICOLOGICAL SCIENCES, 2004, 80 (02) :343-349
[6]   Disturbed Ca2+-signaling by chloroacetaldehyde:: A possible cause for chronic ifosfamide nephrotoxicity [J].
Benesic, A ;
Schwerdt, G ;
Mildenberger, S ;
Freudinger, R ;
Gordjani, N ;
Gekle, M .
KIDNEY INTERNATIONAL, 2005, 68 (05) :2029-2041
[7]   CLINICAL PHARMACOKINETICS OF IFOSFAMIDE IN COMBINATION WITH N-ACETYLCYSTEINE [J].
BENVENUTO, JA ;
AYELE, W ;
LEGHA, SS ;
RABER, MN ;
NICAISE, C ;
NEWMAN, RA .
ANTI-CANCER DRUGS, 1992, 3 (01) :19-23
[8]  
BEUTLER E, 1985, J LAB CLIN MED, V105, P581
[9]   PHARMACOKINETICS OF N-ACETYLCYSTEINE IN MAN [J].
BORGSTROM, L ;
KAGEDAL, B ;
PAULSEN, O .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 31 (02) :217-222
[10]  
BURK RF, 1979, RES COMMUN CHEM PATH, V24, P205